Earnings Results Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings results on July 30, 2026 that exceeded analyst expectations. The Healthcare company reported…
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings results on July 30, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $2.85, beating the consensus estimate of $2.10 by $0.75 per share. Revenue came in at $959.0M, beating the estimate of $876.6M.
Neurocrine Biosciences's stock moved following the earnings release. The stock currently trades at $185.50 with a market capitalization of $15.4B.
Neurocrine Biosciences's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 36% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Neurocrine Biosciences should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
| Quarter | EPS Actual | EPS Est. | Surprise |
|---|---|---|---|
| Q2 (Jul 2026) | $2.85 | $2.10 | +35.7% |
| Q1 (May 2026) | $1.94 | $1.61 | +20.5% |
| Q4 (Feb 2026) | $1.88 | $2.09 | -10.0% |
Related Tools: Earnings Calendar | View NBIX Stock Page
Check the latest earnings dates on our NBIX earnings page or the Earnings Calendar.
See the full Q2 results including EPS actual vs estimate on our NBIX earnings page.
Current market data
NASDAQ · NBIX
$154.03
Up: +$2.73 · +1.77%
Live quote updated
Keep reading
analyst ·
analyst ·
analyst ·
analyst ·
